Guardant Health, Inc. (GH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 500M 1B 1.5B Q2 '18: 67.2M Q3 '18: 77.8M Q4 '18: 90.6M Q1 '19: 110.6M Q2 '19: 145.2M Q3 '19: 184.4M Q4 '19: 214.4M Q1 '20: 245.2M Q2 '20: 257.6M Q3 '20: 271.3M Q4 '20: 286.7M Q1 '21: 297.9M Q2 '21: 323.7M Q3 '21: 343.9M Q4 '21: 373.7M Q1 '22: 391.1M Q2 '22: 408.1M Q3 '22: 430.8M Q4 '22: 449.5M Q1 '23: 482.2M Q2 '23: 510.2M Q3 '23: 535.8M Q4 '23: 563.9M Q1 '24: 603.7M Q2 '24: 643.8M Q3 '24: 692.3M Q4 '24: 739M Q1 '25: 774M Q2 '25: 828.8M Q3 '25: 902.6M Q4 '25: 982M Q1 '26: 1.1B Q2 '26: 1.2B Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q2 '18: -85.6M Q3 '18: -81.2M Q4 '18: -92.9M Q1 '19: -98M Q2 '19: -90.5M Q3 '19: -83.8M Q4 '19: -82.4M Q1 '20: -93.6M Q2 '20: -133M Q3 '20: -189.7M Q4 '20: -254.9M Q1 '21: -327.9M Q2 '21: -370.9M Q3 '21: -404M Q4 '21: -411M Q1 '22: -426.5M Q2 '22: -459.2M Q3 '22: -496.5M Q4 '22: -544.4M Q1 '23: -555.1M Q2 '23: -544.4M Q3 '23: -513.3M Q4 '23: -564.7M Q1 '24: -530.4M Q2 '24: -511.4M Q3 '24: -515.1M Q4 '24: -443.6M Q1 '25: -455M Q2 '25: -460.7M Q3 '25: -442.4M Q4 '25: -437.2M Q1 '26: -447.6M Q2 '26: -470.3M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q2 '18: -79.1M Q3 '18: -75M Q4 '18: -85.1M Q1 '19: -92.6M Q2 '19: -82.2M Q3 '19: -70.9M Q4 '19: -67.9M Q1 '20: -78.3M Q2 '20: -116.8M Q3 '20: -175.3M Q4 '20: -246.3M Q1 '21: -321.8M Q2 '21: -369.6M Q3 '21: -405.5M Q4 '21: -384.8M Q1 '22: -400.6M Q2 '22: -532.5M Q3 '22: -587M Q4 '22: -654.6M Q1 '23: -664.9M Q2 '23: -508.2M Q3 '23: -432.3M Q4 '23: -479.4M Q1 '24: -460.9M Q2 '24: -490.8M Q3 '24: -512.4M Q4 '24: -436.4M Q1 '25: -416.5M Q2 '25: -413.8M Q3 '25: -398.8M Q4 '25: -416.3M Q1 '26: -433.2M Q2 '26: -453.4M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 150M 300M 450M Q4 '24: 289.8M Q1 '25: 299.2M Q2 '25: 308M Q3 '25: 327.1M Q4 '25: 349M Q1 '26: 379.2M Q2 '26: 413.9M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '18: -63.6M Q4 '18: -72.2M Q1 '19: -69.9M Q2 '19: -66.7M Q3 '19: -43.3M Q4 '19: -47.1M Q1 '20: -56.1M Q2 '20: -65.6M Q3 '20: -75M Q4 '20: -103.9M Q1 '21: -106.9M Q2 '21: -146.2M Q3 '21: -191.3M Q4 '21: -209M Q1 '22: -221.3M Q2 '22: -270.7M Q3 '22: -295.7M Q4 '22: -309.5M Q1 '23: -355.3M Q2 '23: -337.4M Q3 '23: -337M Q4 '23: -325M Q1 '24: -280.8M Q2 '24: -280.8M Q3 '24: -254.1M Q4 '24: -239.9M Q1 '25: -272.3M Q2 '25: -238.5M Q3 '25: -222.9M Q4 '25: -184.8M Q1 '26: -187.7M Q2 '26: -185.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '18: -83.9M Q4 '18: -92.4M Q1 '19: -88.8M Q2 '19: -81.3M Q3 '19: -57.9M Q4 '19: -65.9M Q1 '20: -81.7M Q2 '20: -97.7M Q3 '20: -111M Q4 '20: -140.1M Q1 '21: -143.1M Q2 '21: -191.5M Q3 '21: -248.9M Q4 '21: -284.1M Q1 '22: -309.5M Q2 '22: -363.2M Q3 '22: -387.8M Q4 '22: -386.9M Q1 '23: -417.6M Q2 '23: -383.1M Q3 '23: -363.4M Q4 '23: -345.5M Q1 '24: -300.7M Q2 '24: -299.3M Q3 '24: -274.4M Q4 '24: -274.9M Q1 '25: -304.9M Q2 '25: -271.7M Q3 '25: -262.2M Q4 '25: -233.1M Q1 '26: -237.1M Q2 '26: -240.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 96M Q3 '20: 99.6M Q1 '21: 101M Q2 '21: 101.2M Q3 '21: 101.4M Q1 '22: 101.9M Q2 '22: 102M Q3 '22: 102.3M Q1 '23: 102.7M Q2 '23: 108.8M Q3 '23: 117.7M Q1 '24: 121.7M Q2 '24: 122.4M Q3 '24: 123.1M Q1 '25: 123.9M Q2 '25: 124.1M Q3 '25: 124.8M Q1 '26: 131.3M Q2 '26: 132.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q2 '18: -6.98 Q3 '18: -6.16 Q4 '18: -2.80 Q1 '19: -1.94 Q2 '19: -0.32 Q3 '19: 1.48 Q4 '19: -0.85 Q1 '20: -0.84 Q2 '20: -1.28 Q3 '20: -1.92 Q4 '20: -2.58 Q1 '21: -3.38 Q2 '21: -3.77 Q3 '21: -4.05 Q4 '21: -4.00 Q1 '22: -4.12 Q2 '22: -5.41 Q3 '22: -5.93 Q4 '22: -6.41 Q1 '23: -6.50 Q2 '23: -4.92 Q3 '23: -4.07 Q4 '23: -4.32 Q1 '24: -3.96 Q2 '24: -4.13 Q3 '24: -4.28 Q4 '24: -3.56 Q1 '25: -3.39 Q2 '25: -3.35 Q3 '25: -3.21 Q4 '25: -3.31 Q1 '26: -3.39 Q2 '26: -3.49 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.